UNIVERSITY OF KENT
SECTION 1: MODULE SPECIFICATIONS
1. Title of the module:
PHAM1127 - Medicines & Disease 2A – Heart, Renal, Endocrine and Nutrition.
2. School which will be responsible for management of the module:
Medway School of Pharmacy
3. Start date of the module:
Autumn 2014
4. The number of students expected to take the module:
160
5. Modules to be withdrawn on the introduction of this proposed module and consultation with other relevant Schools and Faculties regarding the withdrawal:
Pharmacology & Therapeutics 1: (PHAM1008) and Practitioner and Patient 2: (PHAM 1009), Medicines Design and Manufacture 2: (PHAM1055), Pharmacology and Therapeutics 2: (PHAM 1056)
6. Level of the module (e.g. Certificate [C], Intermediate [I], Honours [H] or Postgraduate [M]):
I
7. The number of credits which the module represents:
40 credits
8. Which term(s) the module is to be taught in (or other teaching pattern):
Term 2
9. Prerequisite and co-requisite modules:
A successful completion of all modules at stage 1 or graduation from the Foundation Degree in Pharmacy practice. Co-requisite modules are Medicines and Disease B and Medicines and Disease C.
10. The programme(s) of study to which the module contributes:
Master of Pharmacy (B230)
11. The intended subject specific learning outcomes and, as appropriate, their relationship to programme learning outcomes
1. Knowledge and understanding of the underlying genetic, immunological and pathological basis of selected diseases (PO 2, 3, 4, 5, 8, 10, 16)
2. Knowledge and understanding of preformulation properties and powder technology in the formulation and manufacture of solid dosage forms (PO 3, 4, 5, 10, 11, 16)
3. An ability to apply drug stability kinetics, modes of pharmaceutical product degradation and the factors affecting stability to evaluate the shelf life and make judgements on suitable storage conditions (PO 3, 4, 10, 16).
4. An understanding of biopharmaceutics, pharmacokinetics and drug metabolism (PO 3, 4, 5, 10, 11, 16).
5. Knowledge of pharmacokinetic data and its interpretation in the light of factors which may affect patient variability (PO 3, 5, 10, 11, 16)
6. Knowledge and understanding of the pharmacological & non pharmacological interventions which are appropriate for the prevention and/or treatment of selected conditions (PO 1, 2, 4, 5, 6, 7, 8, 10, 11, 14, 16)
7. An ability to reflect on and discuss detailed mechanism of drug action as well as the cautions, contraindications and risks associated with certain drug therapies (PO 2, 3, 4, 5, 8, 10, 16)
8. Knowledge and understanding of medical terminology by reviewing patient case notes and analysing the information to begin the process of pharmaceutical care planning (PO 1, 2, 4, 5, 6, 10, 14, 16).
9. A knowledge of the methods used to monitor drugs which require individualised dosing and an ability to interpret associated clinical data (PO 3, 4, 5, 6, 10, 11, 16)
10. An ability to undertake and interpret patient monitoring requirements linked to selected clinical conditions and/or therapeutic interventions (PO 2, 3, 4, 5, 6, 10, 11, 16)
11. An understanding of the patient as an individual including awareness of factors that may influence health behaviour such as age, gender, ethnicity, faith, illness and cultural background (PO 1, 5, 6, 7, 8, 10, 11, 12, 14, 15, 16)
12. An understanding of consultation models based upon concordance to discuss issues related to adherence and medicine taking (PO 1, 2, 5, 8, 10, 14, 15, 16).
13. An understanding of patient assessment with respect to patient history taking and responding to symptoms (PO 1, 2, 4, 5, 6, 8, 10, 11, 14, 15, 16).
14. An increasing understanding of the ethical and legal responsibilities of the pharmacist, including their accountability in relation to supply, dispensing, medical and non-medical prescribing of medicines and appliances (PO 1, 2, 4, 5, 6, 7, 8, 10, 14, 15, 16)
12. The intended generic learning outcomes and, as appropriate, their relationship to programme learning outcomes:
1. Knowledge of the skills necessary for independent learning, problem analysis, oral and written communication (PO 1, 10, 12, 16).
2. Application of verbal and non-verbal communication skills appropriate to the situation (PO 1, 2, 5, 6, 8, 9, 10, 12, 14, 15, 16).
3. An understanding of the roles of other health and social care professionals in relation to improving patient outcomes (PO 1, 5, 6, 8, 10, 14, 15, 16).
4. Ability to undertake pharmaceutical calculations without a calculator, to assure patient safety (PO 4, 6, 7, 10, 16).
13. A synopsis of the curriculum:
Concepts of pharmacotherapeutics, pharmaceutics, chemistry, biosciences, pharmacokinetics and professional practice are integrated to introduce students to the use of drug and non-drug therapy in treating major diseases of selected body systems. The module aims to provide students with an in-depth knowledge of the pathophysiological basis of diseases, management aims, non-pharmacological and pharmacological strategies including the science of drug action. Didactic lectures combined with active learning approaches will enable students to apply clinical and scientific aspects into practice.
Pathological basis of disease
· Selected long term conditions
o Hypertension
o Hyperlipidaemia
o Ischemic heart disease (IHD)-stable angina
o Kidney disease
o Thyroid disorders
o Contraception
o Diabetes
o Dyspepsia
o Peptic ulcer Disease
o Gastro-oesophageal Reflux Disease (GORD)
o Hepatic disorders
· Managing symptoms in the pharmacy (core minor ailments)
Drug Delivery
· Solid dosage forms
· Chemical stability of drugs
· Biopharmaceutics
· Basic pharmacokinetics
· Drug metabolism
Pharmacotherapy
· Cardiovascular system
· Renal
· Endocrine
· Gastrointestinal
· Hepatic
Professional Practice
· Law & Ethics
· Dispensing
· Pharmaceutical calculations
· Medicine Safety
· Placements
14. Indicative Reading List
ISBN Number / Author / Date / Title / Publisher /0443055173 * / Aulton, M.E. / 2001 / Pharmaceutics – The Science of Dosage Form Design / Churchill – Livingstone
0824706749** / Banker, G.S., Rhodes, C.T. / 2002 / Modern Pharmaceutics (Drugs & the Pharmaceutical Sciences S.) / Marcel Dekker Ltd
085369608X* / Florence, A.T., Attwood, D. / 2005 / Physicochemical Principles of Pharmacy / Pharmaceutical Press
0071375503 / Shargel, L., Yu, A.B.C. / 2004 / Applied biopharmaceutics and pharmacokinetics / Appleton and Lange
0853698272 / Appelbe, G.E. & Wingfield J. / 2009 / Dale & Appelbe’s Pharmacy Law and Ethics, 9th Ed. / Pharmaceutical Press
1405180795** / Blenkinsopp, A. Paxton, P. & Blenkinsopp, J. / 2008 / Symptoms in the Pharmacy, 6th Edition / Blackwell Publishing
0853697787* / BMA /RPSGB / 2008 / British National Formulary, 56th Edition / Pharmaceutical Press
0835697831* / RPSGB / 2009 / Medicines, Ethics and Practice Guide, 32nd edition. / Pharmaceutical Press
0853696497** / Wright J, Gray A, Goodey V. / 2006 / Clinical Pharmacy Pocket Companion / Pharmaceutical Press
0323035698* / Page, C.B., Curtis, M., Walker, M., and Hoffman, B. / 2006 / Integrated Pharmacology, 3rd Edition / Mosby
443071454* / Rang H.P., Dale M.M., Ritter J.M., Moore, P.K. & Lamb, P. / 2007 / Pharmacology 6th Edition / Churchill Livingstone
978-0-07-
160405-5 / Katzung, Masters
& Trevor. / 2009 / Basic and Clinical Pharmacology 11th Edition / McGraw Hill
16. Learning and Teaching Methods, including the nature and number of contact hours and the total study hours which will be expected of students, and how these relate to achievement of the intended learning outcomes (SSLO 11.1-14)
Directed Learning and Teaching Activities
Activity / Lectures / Practicals/Workshop(40 students) / Clinical Sessions
(all students) / Experiential learning / MSCL / Total hours / Learning outcomes
Pathological basis of disease and pharmacotherapy / 19 / 3 x 3h / 3 x2h / - / 38 / 72 / 1, 4, 6, 7,
Drug metabolism / 4 / - / - / - / 8 / 12 / 4, 5, 6, 9,
Drug Delivery / 6 / 4 x 3h / 12 / 30 / 2, 3, 4, 5
Biopharmacy & pharmacokinetics / 12 / 3 x 3h / - / - / 24 / 45 / 2, 4, 5, 6, 7, 9,
Chemical Stability of drugs / 4 / 1 x 3h / - / - / 8 / 15 / 2, 3, 9,
Professional Practice / 10 / 4 x 3h / - / - / 20 / 42 / 3, 7, 8, 9, 10, 11, 12, 13, 14,
Private study / - / - / - / - / - / 133
Mock dispensing exam / - / 1 x 3h / - / - / - / 3
Revision seminars / - / 1 x 3h / 1 x 2h / - / - / 5
Clinical placements / - / - / - / 5 x 7h / - / 35
Interim assessments / 1h MCQ
1h dispensing exam
MyFolio (PASS/FAIL)
3h Practical assessment
Formal assessment / 1 x 3h exam
Total hours / 55 / 51 / 8 / 35 / 112 / 400
The module is delivered using a variety of teaching methods to enable students to integrate science with practice of pharmacy to meet all the specific learning outcomes and to acquire knowledge, communication (both written and oral), problem solving and clinical skills. These methods include didactic lectures, practical/workshop sessions and integration sessions.
Lectures are intended to present the key points directly relating to the learning objectives. This will address all subject specific learning outcomes (SSLOs) (11.1-14) as well as generic learning outcome (GLO) 12. 3.
Practical laboratories workshops and clinical integration sessions: serve to reinforce material presented in the lectures and also relate directly to the learning objectives. These are specifically based on clinical cases / scenarios and / or key techniques enabling students to relate their theoretical knowledge to the clinical role of the pharmacist as health professional. This will address SSLOs 11.1-14 and GLOs 12.1-4.
MSCL serves to reinforce and support materials presented in the above forms in the students’ minds. They also form part of the self-directed learning for the student. This will address all SSLOs and GLOs.
Private study encompasses the revising of all material presented in the above various forms of teaching and learning, together with the opportunity to explore and read more widely around specific topics (this may already have been suggested in the MSCL materials). Students should be able to work through the learning objectives and identify key areas that require further revision.
Seminars will constitute interim assessment feedback sessions and revision seminars.
Revision seminars will be delivered to support students with the review of material covered in the module to prepare them for the final examination. This will address all learning outcomes.
15. Assessment methods and how these relate to testing achievement of the intended learning outcomes:
Methods ofAssessment / Learning outcomes assessed / Weighting / Outline Details /
Continuous Assessment / All / 40%
PASS required
PASS required / Interim assessment (40%)
Written assessment (40%)
Class Tests (20%)
Competency assessment (dispensing exam)
Satisfactory attendance and performance at all scheduled coursework sessions (workshops, laboratories, and seminars) **
Examination / All / 60% / 1 X 3 hour Examination
Pass Mark
The pass mark for this module is 40% overall. It should also be noted that neither compensation nor condonement would normally be granted.
** Satisfactory attendance and performance at all scheduled coursework sessions is normally defined as a minimum of 80% attendance (all classes excluding lectures) plus lab books/ worksheets maintained to the required standard.
Attendance of less than 80% will constitute a FAIL and will result in a capped continuous assessment mark unless a concession form supported by medical evidence is completed in accordance with the School guidelines, in which case attendance of less than 60% will result in FAIL.
16. Implications for learning resources, including staff, library, IT and space
None
17. The School recognises and has embedded the expectations of current disability equality legislation, and supports students with a declared disability or special educational need in its teaching. Within this module we will make reasonable adjustments wherever necessary, including additional or substitute materials, teaching modes or assessment methods for students who have declared and discussed their learning support needs. Arrangements for students with declared disabilities will be made on an individual basis, in consultation with the University’s disability/dyslexiasupport service, and specialist support will be provided where needed.
The curriculum, learning and teaching methods and forms of assessment do not present any non-justifiable disadvantages to students with disabilities. However the requirements of Fitness to Practise for Pharmacy students as determined by the professional regulator for pharmacy, the General Pharmaceutical Council apply to the MPharm programme.
If the module is part of a programme in a Partner College or Validated Institution, please complete the following:
18. Campus(es) where module will be delivered:
Medway campus
19. Partner College / Validated Institution:
20. University School (for cognate programmes) or Faculty (for non-cognate programmes) responsible for the programme:
Medway School of Pharmacy
SECTION 2: MODULE IS PART OF A PROGRAMME OF STUDY IN A UNIVERSITY SCHOOL
Statement by the School Director of Learning and Teaching/School Director of Graduate Studies (as appropriate): "I confirm I have been consulted on the above module proposal and have given advice on the correct procedures and required content of module proposals"
Director of Learning and TeachingBugewa Apampa
Print Name / Date
Statement by the Head of School: "I confirm that the School has approved the introduction of the module and, where the module is proposed by School staff, will be responsible for its resourcing"
Head of SchoolIain Cumming
Print Name / Date
1